{
    "functional_evidence_assessment": [
        {
            "variant_id": {
                "Gene": "a - synuclein",
                "Protein_Change": {
                    "ref": "E",
                    "alt": "K",
                    "position": "46"
                },
                "variant_string_id": "a - synuclein E46K"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are neuropathologically defined by nerve cell loss, presence of Lewy bodies and Lewy neurites. Missense mutations (A30P, A53T, E46K) in a - synuclein and overproduction of wild - type protein cause familial forms of these diseases. a - Synuclein is the major component of the filamentous Lewy bodies and Lewy neurites.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that mutations in a - synuclein can cause PD and DLB, and describes the neuropathological features related to these diseases and the role of a - synuclein in them.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "Liposome pull - down assay was used to investigate lipid binding and ThT fluorescence and electron microscopy were used to study filament assembly. These assays are relevant as a - synuclein's lipid binding and filament assembly are related to the disease mechanism of PD and DLB.",
                    "judgment": "Yes",
                    "reasoning": "The liposome pull - down assay to study lipid binding and the methods to study filament assembly effectively model the disease pathogenesis as a - synuclein's abnormal lipid binding and filament assembly are associated with the disease mechanism. ",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "sub_step": "3a: Basic Controls and Replicates",
                    "extracted_paper_info": "The results are presented as means ± S.E.M. of the measurements obtained from three independent protein preparations, each run in duplicate for liposome binding assays. For filament assembly, control experiments with wild - type a - synuclein had established that the continuous presence of ThT did not affect assembly.",
                    "judgment": "Yes",
                    "reasoning": "Multiple replicates (three independent protein preparations, each run in duplicate) were used for liposome binding assays. Also, wild - type a - synuclein was used as a control in filament assembly experiments, meeting both basic control and replicate requirements.",
                    "next_step_or_outcome": "Proceed to Sub - step 3c"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "sub_step": "3c: Variant Controls",
                    "extracted_paper_info": "A30P and A53T, which are known pathogenic mutations, were used as controls in the same assays as E46K to study lipid binding and filament assembly.",
                    "judgment": "Yes",
                    "reasoning": "Known pathogenic variants (A30P and A53T) were used as controls in the assays for the E46K variant.",
                    "next_step_or_outcome": "Proceed to Step 4"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation",
                    "sub_step": "4a: Statistical Analyses",
                    "extracted_paper_info": "The results are presented as means ± S.E.M., but there is no mention of calculating OddsPath or statistical tests to estimate OddsPath.",
                    "judgment": "No",
                    "reasoning": "The paper does not provide information on calculating OddsPath or relevant statistical tests for the functional data of the E46K variant.",
                    "next_step_or_outcome": "Proceed to Sub - step 4b"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation",
                    "sub_step": "4b: No OddsPath Calculation",
                    "extracted_paper_info": "Two known pathogenic variants (A30P and A53T) were used as controls in the assays related to E46K.",
                    "judgment": "10 or less",
                    "reasoning": "Only 2 known pathogenic variant controls (A30P and A53T) were used in the assays related to E46K, which is 10 or less.",
                    "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The E46K variant in a - synuclein was studied using relevant assays with proper controls and replicates. Known pathogenic variants were used as controls. However, due to lack of OddsPath calculation and a small number (2) of total benign/pathogenic variant controls, the functional evidence strength is PS3_supporting."
        }
    ]
}